Meet the innovator - Lucida

web header 2026

Lucida Medical

AI solution supporting prostate cancer diagnosis.

Grow Companies quotes 2026 Lucida

 

 

Problem 

NHS Trusts are under increasing pressure to deliver timely prostate cancer care while managing growing demand and limited resources. Common challenges include:
  • Managing increasing volumes of prostate MRI examinations
  • Prioritising patients most likely to have clinically significant disease
  • Avoiding unnecessary procedures and associated costs
Failure to address these challenges can lead to inefficiencies across the pathway and impact patient experience.

Solution 

Lucida Medical has developed Pi™ (Prostate Intelligence), an AI solution that supports prostate cancer diagnosis.

Pi™  supports the prostate diagnosis pathway by interpreting prostate magnetic resonance imaging (MRI), automatically risk stratifying each patient based on the likelihood of clinically significant prostate cancer and producing automated visual outputs and calculations to support clinical workflows.  

Pi™ can be used to support the diagnosis pathway in different ways:  

  • To automatically book high-risk patients for the next available biopsy at a pre-determined Pi™ score threshold (bypassing MRI reporting and administration)  
  • To enable radiologists to prioritise patients at greatest risk of prostate cancer when reporting MRI results, and providing a ‘second read’ for clearer negative cases (previously done by a second radiologist)  
  • To produce 3D heatmap images and calculate the prostate volume to support biopsy decisions and procedures.  

Impact 

The main benefits of Pi™ are: 

Benefits for patients 

  • Enables earlier diagnosis of clinically significant cancer, helping improve patient outcomes. 
  • Improves accuracy when referring patients for biopsy and supports more precise prostate biopsies. 

Benefits for radiologists 

  • Supports meeting the 28-day Faster Diagnosis Standard from referral to diagnosis or ruling out cancer. 
  • May reduce unnecessary biopsies by up to 20%, saving around £139 per patient over their lifetime. 
  • Reduces reliance on outsourced teleradiology, helping lower costs. 
  • Enables faster triage of high-risk patients and quicker reporting of normal prostate MRIs. 
  • Improves diagnostic accuracy for less experienced radiologists and registrars. 

Benefits for urologists 

  • Accurate lesion contouring and prostate segmentation may enable nurse-led biopsy services, expanding capacity and helping address resource constraints. 
  • Improves the accuracy and precision of biopsy procedures by overlaying AI outputs onto MRI scans, allowing better targeting of lesions. 
  • Particularly useful for detecting prostate cancer in harder-to-diagnose areas, such as the anterior zone. 

Find out more about Lucida Medical on their website